Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s):  CRDL | T.CRDL.W.A

Healthcare
Cardiol Therapeutics Inc. (Cardiol) is a Canada-based clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). The Company's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive... see more

Recent & Breaking News (TSX:CRDL)

IIROC Trading Halt - CRDL

Canada NewsWire May 5, 2021

Cardiol Therapeutics Announces $15 Million Bought Deal Public Offering

GlobeNewswire May 5, 2021

Cardiol Therapeutics Announces First Patient Enrolled in LANCER, a Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19

Newsfile April 28, 2021

Cardiol (TSX:CRDL) announces topline results from Phase I trial for CardiolRx

Trevor Abes  April 12, 2021

Cardiol Therapeutics Announces Topline Results from Phase I Single and Multiple Ascending Dose Clinical Trial of CardiolRx(TM)

Newsfile April 12, 2021

Cardiol Therapeutics Announces Filing of 2020 Year-End Financial Statements and MD&A

Newsfile April 1, 2021

Cardiol Therapeutics (TSX:CRDL) appoints Dr. Andrew Hamer as new Chief Medical Officer

Julia Kennedy  March 30, 2021

Cardiol Therapeutics Appoints Dr. Andrew Hamer as New Chief Medical Officer

Newsfile March 30, 2021

Cardiol (TSX:CRDL) applies for Nasdaq uplisting and raises over $10 million from warrants and options

Trevor Abes  March 2, 2021

Cardiol Therapeutics Submits Application for Uplisting to the Nasdaq and Raises Proceeds of Over $10 Million from Exercise of Warrants and Options

Newsfile March 2, 2021

TMX Group, Cardiol Therapeutics, C-Suite at The Open

Canada NewsWire February 4, 2021

Cardiol Therapeutics Announces Formation of Data Safety Monitoring and Clinical Endpoint Committees for Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19

Newsfile January 21, 2021

Cardiol Therapeutics to Participate in Upcoming Virtual Investor Conferences

Newsfile January 7, 2021

Cardiol Therapeutics Announces Completion of Phase I Clinical Study of CardiolRx(TM)

Newsfile December 22, 2020

Cardiol Therapeutics Appoints Worldwide Clinical Trials as CRO for the Company's Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19

Newsfile December 15, 2020

Cardiol Therapeutics' Cortalex(TM) CBD Now Available Exclusively Online at Medical Cannabis by Shoppers Inc.

Newsfile October 20, 2020

FDA Approves Landmark COVID/Heart/CBD Clinical Trial -- SECFilings.com

Newsfile September 30, 2020

IIROC Trade Resumption - CRDL

Canada NewsWire September 25, 2020

Cardiol Therapeutics Receives FDA Approval for Investigational New Drug (IND) Application for Phase II/III COVID-19 Trial

Newsfile September 25, 2020

IIROC Trading Halt - CRDL

Canada NewsWire September 24, 2020